Market News & Trends
TYME Announces First Patient Dosed in Pivotal Trial
Tyme Technologies, Inc. recently announced the first pancreatic cancer patient has been dosed in Part 2 of the TYME-88-Panc pivotal trial designed to support approval…
Bayer Exercises Right to Enter Follow-On Research & Collaboration Option Agreement
Bayer and Atomwise, the leader in artificial intelligence (AI) for drug discovery, recently announced the companies will continue the development of two crop protection programs.…
ArTara Therapeutics Completes Merger Transaction With Proteon Therapeutics
ArTara Therapeutics, Inc. recently announced the completion of the merger with Proteon Therapeutics, Inc.and associated equity financing. The merged company will operate under the name…
Patent Filed for Nitric Oxide Delivery Device That is Comparable to Inhalers
Nu-Med Plus, Inc., a medical device development company, recently announced that a patent has been filed for a nitric oxide delivery device that is designed for…..
New Publication Demonstrates GeneSight Improved All Clinical Outcomes Using HAM-D6 Analysis in Large Prospective GUIDED Study
Myriad Genetics, Inc. recently announced that a new analysis of the GUIDED clinical trial using the 6-item Hamilton Depression Rating Scale (HAM-D6) was published online in BMC Psychiatry. The key finding is….
Cytovia Therapeutics & the University of California, San Francisco Enter Partnership to Develop Precision Gene-Edited CAR-NK Cell Therapy
Cytovia Therapeutics and the University of California, San Francisco (UCSF) recently announced they have entered a 3-year research partnership to develop novel precision gene editing…
Acceleron & Fulcrum Therapeutics Announce Pulmonary Research & Discovery Collaboration Agreement
Acceleron Pharma Inc. and Fulcrum Therapeutics, Inc. recently announced they have entered into a collaboration and license agreement to identify small molecules designed to modulate…
WuXi STA Opens Oligonucleotide Large-Scale Manufacturing Facility
STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – recently announced the opening of its large-scale oligonucleotide active pharmaceutical ingredient (API)…
Pfenex Earns $15-Million Development Milestone Under its Development & License Agreement
Pfenex Inc. recently announced it has earned a $15-million development milestone under its development and license agreement with Jazz Pharmaceuticals plc. The milestone is associated…
Opiant Pharmaceuticals Announces Development Collaboration With National Center for Advancing Translational Sciences
Opiant Pharmaceuticals, Inc. recently announced it has signed a Letter of Intent with the National Center for Advancing Translational Sciences (NCATS) to collaborate on the…
FDA Approves Intra-Cellular Therapies’ Novel Treatment of Schizophrenia in Adults
Intra-Cellular Therapies, Inc. recently announced that CAPLYTA (lumateperone) has been approved by the US FDA for the treatment of schizophrenia in adults. The company expects…
Celgene Had the Highest R&D Spend in 2018
Large pharmaceutical companies are investing a disproportionately large amount of annual revenue in research and development (R&D), according to GlobalData’s Company Financials database. An analysis…
Catalent Launches New CTSuccess(TM) Service to Guide Sponsors to Smarter Clinical Trial Supply Planning
Catalent, a global leader in clinical supply services, recently announced the launch of its new CTSuccessTM clinical trial planning service, designed to support trial sponsors…
Bioiberica Launches Natural Origin Thyroid
Bioiberica, a world reference in the identification, extraction, and development of animal-derived APIs, recently announced the launch of its natural thyroid active pharmaceutical ingredient (API) for the treatment of…..
Tetra Bio-Pharma Provides Update on its Hepatocellular Carcinoma Drug
Tetra Bio-Pharma Inc. recently announced it will be requesting a meeting with the US FDA to discuss the drug development program for its Orphan Drug candidate HCC011….
Catalent Partners With Bridge Therapeutics on Formulation, Development & Production of New Opioid Addiction Treatment
Catalent recently announced it has completed clinical production of Bridge Therapeutics Inc.’s (Bridge) opioid addiction development therapeutic product, BT-219, and executed an….
Diagnosed Prevalent Cases of Chronic Heart Failure to Reach 32 Million
Nearly 40% of all diagnosed prevalent cases of Chronic Heart Failure (CHF) in the eight major markets (8MM) occur in the elderly population, and this is estimated to increase by a further….
Tonix Pharmaceuticals Enrolls First Patient in Phase 3 RELIEF Study
Tonix Pharmaceuticals Holding Corp. recently announced that the first patient was enrolled in the Phase 3 RELIEF study (TNX-CY-F304)……
Beta Bionics Receives FDA Breakthrough Device Designation
Beta Bionics, Inc. recently announced it has received Breakthrough Device designation from the US FDA for its investigational iLet Bionic Pancreas System. The iLet Bionic…
Inceptua Medicines Access & Onconova Therapeutics Announce Pre-Approval Access Collaboration
Onconova Therapeutics, Inc. and Inceptua Medicines Access (a business unit of the Inceptua Group) recently announced they have entered into a collaboration to make available…